PHILADELPHIA, Sept. 19, 2013 /PRNewswire/ --The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today released Big Data and the Needs of the Pharma Industry, a whitepaper offering new strategies for managing Big Data, most specifically by using an array of technologies to convert it into more meaningful, accessible Little Data. The paper highlights how the inherently data-driven pharmaceutical industry requires deep, broad information to feed drug R&D, but the way it processes Big Data is unique.
"The Big Data opportunity in pharma means linking a variety of content across silos," said Tim Miller, vice president of Thomson Reuters Life Sciences. "Thomson Reuters is focused on making that content work at a human level, we use ontologies and analytics to turn Big Data into actionable Little Data."
The whitepaper addresses the concept that innovation in information processing involves creating environments where data has a relevant and accessible flow. It requires the ability to break down the walls between internal, external, public and commercial content and give customers the tools they need to work across them. Solutions from Thomson Reuters, Accelrys, DataSift, Entagen, and GenoSpace shed light on the burgeoning business of converting Big Data into actionable Little Data.Thomson Reuters Life Sciences analysts and experts explore the evolution of Big Data in pharma and the industry's current needs. The findings are based on a recent Thomson Reuters survey conducted with a group of pharmaceutical IT experts to determine the challenges and opportunities Big Data presents. Respondents overwhelmingly agreed that drug discovery and market understanding were the two greatest opportunities for the industry. They also agreed that the biggest challenge of Big Data is its manageability and how to connect data from various internal and external places to feed the innovation process.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV